Oriola-KD to acquire Svensk Dos

4.12.2015

Oriola-KD Corporation Press Release 3 December 2015 at 09.30 a.m. (Finnish time)

Oriola-KD to acquire Svensk Dos

Oriola-KD has signed a definite agreement with all of the shareholders of Svensk Dos to acquire Swedish pharmacy company Svensk Dos. The Svensk Dos is specialized in dose dispensing of pharmaceuticals. Today Svensk Dos provides dose dispensed medicines to 24,000 people via extradition locations and nursing homes in the region of Skåne and direct to the Swedish Prison and Probation Service all over Sweden. In 2014, the net sales of Svensk Dos were approximately MEUR 25 and estimated market share was 13 %. Svensk Dos has also been awarded a contract in Sjuklövern cluster region (Gävleborg, Västmanland, Sörmland, Uppsala, Värmland, Dalarna och Örebro) of dose dispensing of pharmaceuticals to 42,500 patients. The Sjuklövern contract is currently under appeal. The Svensk Dos has approximately 60 employees and is based in Uppsala.

The purchase price is not published. Oriola-KD will use its existing financing facilities to finance the acquisition. The transaction is expected to be completed in the first quarter of 2016 and is subject to the approvals of the Competition Authority and the Medical Products Agency in Sweden.

"The acquisition of Svensk Dos is an important addition into our new Healthcare business. Through this acquisition we can complement our growing service offering to the Healthcare sector", says Eero Hautaniemi, President and CEO, Oriola-KD.

"I'm extremely happy for this deal. This allows us to strengthen our partnership with the County councils and the entire healthcare arena. I would also like to warmly welcome the new competent professionals into our company to pave the growth of our healthcare services", says Thomas Gawell, VP, Healthcare business, Oriola-KD.

Oriola-KD Corporation

Eero Hautaniemi

President and CEO

Further information:

Eero Hautaniemi

President and CEO

Tel. +358 (0)10 429 2109

e-mail: eero.hautaniemi@oriola-kd.com

Thomas Gawell

Vice President, Healthcare Business

Tel. + 46 31 88 70 42

e-mail: thomas.gawell@oriola.com

More news

17.03.2024 | News

Want to nail pharma marketing compliance in the Nordics while still doing brilliant promotion? Welcome to Oriola’s breakfast event!

The Medical and Scientific Affairs Team of Oriola’s Advisory Services is pleased to invite you to a complimentary breakfast event in Stockholm on April 16th, 2024.

22.02.2024 | News

How pharmacists perceive your product – get insight of the Finnish market from our pharmacy opinion surveys

Oriola’s pharmacy opinion surveys shed light on overall market or therapy area related trends, how medical products are perceived and what is the competitive environment. Combined with sales data, these analyses support pharmaceutical companies in better understanding the Finnish market.

10.01.2024 | News

Apteekkisydän pharmacy in Naantali recognised as the Research Pharmacy of the Year 2023

Information acquired from patients is increasingly used in pharmacotherapy decision making to assess for example the effectiveness and cost effectiveness of treatment. Apteekkisydän pharmacy in Naantali gained the Research Pharmacy of the Year 2023 recognition from its active participation in conducting patient surveys. Research pharmacies in Finland are an internationally unique concept for collecting patients’ own experiences from their treatment.